Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome

Psychoneuroendocrinology

Volumn 37, Issue 12, 2012, Pages 1901-1911

  Beumer, Wouter ^a   Drexhage, Roosmarijn C ^a   De Wit, Harm ^a   Versnel, Marjan A ^a   Drexhage, Hemmo A ^a   Cohen, Dan ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Severe Mental Illness   (Netherlands)

Author keywords

Adipokines; Adiponectin; CCL2; CCL4; Chemokines; Cytokines; Diabetes; ICAM 1; IL 1 ; IL 6; Leptin; Macrophages; Metabolic syndrome; Monocytes; OPG; PAI 1; PTX3; Schizophrenia; TNF

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATYPICAL ANTIPSYCHOTIC AGENT; CHEMOKINE; CLOZAPINE; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROLEPTIC AGENT; OLANZAPINE; OSTEOPROTEGERIN; PENTRAXIN 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENDER; HUMAN; HYPERGLYCEMIA; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MONOCYTE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADIPOKINES; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; HYPERGLYCEMIA; IMMUNOLOGIC FACTORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84869873085     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.04.001     Document Type: Article

References (56)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2007, 90:179-185.
2. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
3. American Psychiatric Association Diagnostic Criteria From DSM-IV-TR 2000, American Psychiatric Association, Washington, D.C.
4. Carrizo E., Fernandez V., Quintero J., Connell L., Rodriguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008, 103:83-93.
5. Cohen D., Batstra M.R., Gispen-de Wied C.C. Immunological characteristics of diabetes in schizophrenia. Diabetologia 2005, 48:1941-1942.
6. Cohen D., Dekker J.J., Peen J., Gispen-de Wied C.C. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol. 2006, 16:187-194.
7. Cohen D., Stolk R.P., Grobbee D.E., Gispen-de Wied C.C. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006, 29:786-791.
8. De Hert M., Cohen D., Bobes J., Cetkovich-Bakmas M., Leucht S., Ndetei D.M., Newcomer J.W., Uwakwe R., Asai I., Moller H.J., Gautam S., Detraux J., Correll C.U. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011, 10:138-151.
9. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemiol. Ment. Health 2006, 2:14.
10. de Leon J., Diaz F.J., Rogers T., Browne D., Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr. Res. 2002, 56:47-54.
11. De Taeye B., Smith L.H., Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr. Opin. Pharmacol. 2005, 5:149-154.
12. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 2011, 36:78-86.
13. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 2008, 8:1955-1962.
14. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., Drexhage H.A. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol. 2011, 14:746-755.
15. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10:59-76.
16. Drexhage R.C., Padmos R.C., de Wit H., Versnel M.A., Hooijkaas H., van der Lely A.J., van Beveren N., deRijk R.H., Cohen D. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?. Schizophr. Res. 2008, 102:352-355.
17. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 2010, 1-13.
18. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
19. Haddy N., Sass C., Maumus S., Marie B., Droesch S., Siest G., Lambert D., Visvikis S. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet. 2005, 13:109-117.
20. Hope S., Melle I., Aukrust P., Agartz I., Lorentzen S., Steen N.E., Djurovic S., Ueland T., Andreassen O.A. Osteoprotegerin levels in patients with severe mental disorders. J. Psychiatry Neurosci. 2010, 35:304-310. 10.1503/jpn.090088.
21. Hummer M., Malik P., Gasser R.W., Hofer A., Kemmler G., Moncayo Naveda R.C., Rettenbacher M.A., Fleischhacker W.W. Osteoporosis in patients with schizophrenia. Am. J. Psychiatry 2005, 162:162-167.
22. Janssen D.G., Caniato R.N., Verster J.C., Baune B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 2010, 25:201-215.
23. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
24. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., Ohtsuka-Kowatari N., Kumagai K., Sakamoto K., Kobayashi M., Yamauchi T., Ueki K., Oishi Y., Nishimura S., Manabe I., Hashimoto H., Ohnishi Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Nagai R., Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 2006, 281:26602-26614.
25. Keefe B. Interferon-induced depression in hepatitis C: an update. Curr. Psychiatry Rep. 2007, 9:255-261.
26. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 2009, 12:561-578.
27. Koller E., Schneider B., Bennett K., Dubitsky G. Clozapine-associated diabetes. Am. J. Med. 2001, 111:716-723.
28. Koller E.A., Cross J.T., Doraiswamy P.M., Schneider B.S. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003, 23:735-744.
29. Koller E.A., Doraiswamy P.M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22:841-852.
30. Koller E.A., Weber J., Doraiswamy P.M., Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry 2004, 65:857-863.
31. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:520-527.
32. Loffler S., Klimke A., Kronenwett R., Kobbe G., Haas R., Fehsel K. Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J. Clin. Psychopharmacol. 2010, 30:591-595.
33. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 1997, 26:221-225.
34. Maudsley H. The Pathology of Mind 1879, Macmillan and Co., London.
35. Meyer J.M., Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann. Clin. Psychiatry 2006, 18:43-48.
36. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
37. Mitchell A.J., Malone D. Physical health and schizophrenia. Curr. Opin. Psychiatry 2006, 19:432-437.
38. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Moller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121:118-124.
39. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159:1029-1034.
40. National Cholesterol Education Program (U.S.), Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III): final report. The Program, Washington, D.C.
41. O'Connor M.F., Bower J.E., Cho H.J., Creswell J.D., Dimitrov S., Hamby M.E., Hoyt M.A., Martin J.L., Robles T.F., Sloan E.K., Thomas K.S., Irwin M.R. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav. Immun. 2009, 23:887-897.
42. Padmos R.C., Hillegers M.H., Knijff E.M., Vonk R., Bouvy A., Staal F.J., de Ridder D., Kupka R.W., Nolen W.A., Drexhage H.A. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65:395-407.
43. Padmos R.C., Schloot N.C., Beyan H., Ruwhof C., Staal F.J., de Ridder D., Aanstoot H.J., Lam-Tse W.K., de Wit H., de Herder C., Drexhage R.C., Menart B., Leslie R.D., Drexhage H.A. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 2008, 57:2768-2773.
44. Rosenbaum M., Nicolson M., Hirsch J., Heymsfield S.B., Gallagher D., Chu F., Leibel R.L. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J. Clin. Endocrinol. Metab. 1996, 81:3424-3427.
45. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
46. Saad M.F., Damani S., Gingerich R.L., Riad-Gabriel M.G., Khan A., Boyadjian R., Jinagouda S.D., el-Tawil K., Rude R.K., Kamdar V. Sexual dimorphism in plasma leptin concentration. J. Clin. Endocrinol. Metab. 1997, 82:579-584.
47. Sarov-Blat L., Kiss R.S., Haidar B., Kavaslar N., Jaye M., Bertiaux M., Steplewski K., Hurle M.R., Sprecher D., McPherson R., Marcel Y.L. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1115-1122.
48. Schwarz M.J., Riedel M., Ackenheil M., Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 2000, 47:29-33.
49. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. (quiz 34-57).
50. Silberstein S., Vogl A.M., Bonfiglio J.J., Wurst W., Holsboer F., Arzt E., Deussing J.M., Refojo D. Immunology, signal transduction, and behavior in hypothalamic-pituitary-adrenal axis-related genetic mouse models. Ann. N. Y. Acad. Sci. 2009, 1153:120-130.
51. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses 1992, 39:248-257.
52. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 45:135-141.
53. Soczynska J.K., Kennedy S.H., Goldstein B.I., Lachowski A., Woldeyohannes H.O., McIntyre R.S. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology 2009, 30:497-521.
54. van der Weerd K., Dik W.A., Schrijver B., Schweitzer D.H., Langerak A.W., Drexhage H.A., Kiewiet R.M., van Aken M.O., van Huisstede A., van Dongen J.J., van der Lelij A.J., Staal F.J., van Hagen P.M. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. Diabetes 2012, 61:401-408.
55. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
56. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.